Illumina Archives

In Depth 29 Sep 2023

Illumina: DNA giant in troubled waters

A botched acquisition deal and unrest among company investors amid plummeting stocks have plagued Illumina, which was once part of the biotech big leagues that dominated the field of gene sequencing. Now, in fear of losing its ground to other players in the space, it has received a European Commission order to divest Grail, and […]

September 29, 2023 - 8 minutesmins - By Roohi Mariam Peter

Genome Sequence Human Genome Update Feature Header

In Depth 4 Sep 2018

The Past, Present and Future of Genome Sequencing

The last two decades have seen a revolution in genome sequencing with dramatic increases in speed and efficiency coupled with massive reductions in cost. There is so much going on in this area it can be difficult to keep up, so here is what you should know. Gene sequencing has proved its usefulness as a […]

September 4, 2018 - 9 minutesmins - By Editorial Team

News and Trends 17 Apr 2018

How Low Can the Price of a Next Generation DNA Sequencer Go?

The next generation of DNA sequencers has arrived, and with it, a clash of titans: Illumina, Thermo Fisher and Qiagen are all competing for the clinical diagnostics market. Next-generation sequencing (NGS) companies are redefining DNA sequencing. What began as small-scale PCR and Sanger sequencing efforts have now mushroomed into a $20Bn market with broad medical implications for […]

April 17, 2018 - 5 minutesmins - By External Contributor

News and Trends 30 Jan 2018

Update: Pocket Device makes its Debut in Whole Human Genome Sequencing

Update (30/01/2018): Oxford Nanopore has published a study in Nature Biotechnology outlining the first use of its pocket MinION device to sequence a human genome. The device was able to read sequences of DNA that are “hundreds of times larger than usual,” helping scientists better reconstruct the whole genome sequence. MinION costs less than $1,000 and […]

January 30, 2018 - 3 minutesmins - By Clara Rodríguez Fernández

News and Trends 12 Sep 2017

French Startup Raises €11M in Series A to Reinvent DNA Synthesis

DNA Script has gathered the support of key international investors to take a new, faster DNA synthesis technology closer to the market. In a Series A round led by Illumina Ventures and joined by Merck Ventures and existing investors Sofinnova Partners, Kurma Partners, and Idinvest Partners, the young French startup DNA Script has raised a total […]

September 12, 2017 - 3 minutesmins - By Clara Rodríguez Fernández

News and Trends 11 Apr 2017

Illumina Enters Europe to Take Over the Prenatal Diagnostics Market

Illumina has launched its NGS-based non-invasive prenatal test (NIPT) in Europe and is ready to position itself as the top dog in this competitive market. The US next-generation sequencing (NGS) giant Illumina has launched its VeriSeq NIPT Solution in the EU today. It’s an NGS-based kit that allows for rapid testing of the fetal chromosome status using a single maternal […]

April 11, 2017 - 2 minutesmins - By Melanie De Almeida

News and Trends 27 Mar 2017

You Can Now Search Worldwide Genomic Data in a Single Platform

Access to data is still the main bottleneck for genomic researchers. Repositive has created a free online platform to solve this problem once and for all. Repositive is building an online platform that makes genomic data from different sources easily searchable and accessible from a single portal. Its mission is to speed up genetic diagnostics […]

March 27, 2017 - 5 minutesmins - By External Contributor

News and Trends 2 Mar 2017

There’s a New Record in Biotech Fundraising: Should We Believe the Hype?

Illumina’s cancer diagnostics baby, GRAIL, has raked in a jaw-dropping $1B in Series B. Should Europe get on America’s level? A new genome sequencing company spun out of Illumina, GRAIL, has raised over $900M in a Series B fundraising round. That’s far and away the largest round ever; further, that’s more than most companies hope to be worth, […]

March 2, 2017 - 5 minutesmins - By Evelyn Warner

News and Trends 2 Nov 2016

NHS adopts Next-Gen Sequencing to Test for Birth Defects

Despite a lawsuit from Illumina, Premaitha forged ahead with its NGS-based non-invasive prenatal test; the NHS just adopted it as a standard screen. With its seemingly infinite applications, next-generation sequencing (NGS) is a hot area, especially for diagnostics biotechs. A number have been founded in recent years to develop prenatal tests for birth defects, and […]

November 2, 2016 - 3 minutesmins - By Evelyn Warner

deskgen desktop genetics biotech labiotech refresh crispr

News and Trends 5 Jul 2016

“CRISPR is highly fragmented, with too many approaches. We bring it all together”

The problem with CRISPR, is that not many people are actually experts in the field, and there are only a select few who worked on it pre-2013. So how did this UK Startup make a big name for itself in field of the ‘Biotech Breakthrough of the Century’? Desktop Genetics is a startup founded in 2012 by three […]

July 5, 2016 - 4 minutesmins - By Dani Bancroft

News and Trends 26 Apr 2016

Illumina is Suing over NGS Prenatal Screening… Again

Genoma is being sued by Illumina over four patents covering technology for prenatal testing, that uses NGS to diagnose fetal defects. After suing Oxford Nanopore over porin technology, Illumina is back to another contentious field – their patents for a type of non-invasive prenatal testing (NIPT). Illumina has filed a patent infringement suit in the Federal […]

April 26, 2016 - 2 minutesmins - By Denise Neves Gameiro

News and Trends 25 Feb 2016

NGS Battle: Illumina is now suing Oxford Nanopore (and it looks suspicious)

NGS-Giant Illumina (US) is suing Oxford Nanopore (UK), the Unicorn ready to disrupt gene sequencing. What’s the story? Illumina currently has the monopoly on NGS equipment, and Illumina’s machines make a common (and bulky) fixture in labs all over the world. In the future, many hospitals will move into data-driven medicine and NGS plays an important […]

February 25, 2016 - 3 minutesmins - By Denise Neves Gameiro

Resources

Categories

The biggest private biotech investments in August 2024

Long non-coding RNAs: what’s behind the growing “dark genome” buzz?

Approaches

Therapeutic areas

Grab your free report on 3D organoids and explore their future potential

Six biotech companies that could revolutionize obesity treatments

R&D

BD

World biotech leaders

Connect with decision-makers and researchers worldwide for collaborative opportunities

Company

Join Us

Subscribe to our newsletter

Advertise with us